86.18

1.35% -1.18

After Hours: 86.01 -0.17 -0.20%

Monopar Therapeutics Inc (MNPR)

Overview News Price History Financials Discussions Forecast

Monopar Therapeutics Inc stock is traded at $86.18, with a volume of 82,436. It is down -1.35% in the last 24 hours and up +7.83% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Previous Close:

$87.36

Open:

$87.66

24h Volume:

82,436

Relative Volume:

0.82

Market Cap:

$575.91M

Revenue:

Net Income/Loss:

$-7.12M

P/E Ratio:

-37.47

EPS:

-2.3

Net Cash Flow:

$-6.82M

1W Performance:

-5.88%

1M Performance:

+7.83%

6M Performance:

+165.50%

1Y Performance:

+316.33%

1-Day Range:

$84.00

$91.79

1-Week Range:

$83.86

$100.50

52-Week Range:

$19.87

$105.00

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name

Monopar Therapeutics Inc

Sector

Healthcare (1139)

Industry

Biotechnology (638)

Phone

(847) 388-0349

Address

1000 SKOKIE BLVD SUITE 350, WILMETTE

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

MNPR's Discussions on Twitter

Compare MNPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNPR Monopar Therapeutics Inc	86.18	583.79M	0	-7.12M	-6.82M	-2.30
VRTX Vertex Pharmaceuticals Inc	433.61	109.65B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.19	82.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	451.23	58.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	911.98	56.50B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.77	43.62B	447.02M	-1.18B	-906.14M	-6.1812

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-25	Initiated	Leerink Partners	Outperform
Oct-13-25	Initiated	Barclays	Overweight
Sep-09-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	Oppenheimer	Outperform
Sep-03-25	Initiated	Raymond James	Strong Buy
Aug-26-25	Resumed	H.C. Wainwright	Buy
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight
Jun-23-25	Initiated	Chardan Capital Markets	Buy
Mar-19-25	Resumed	Piper Sandler	Overweight
Jan-10-25	Initiated	Piper Sandler	Overweight
Oct-11-24	Initiated	Rodman & Renshaw	Buy
Jan-28-21	Initiated	ROTH Capital	Buy

View All

Monopar Therapeutics Inc Stock (MNPR) Latest News

Nov 27, 2025

Is Monopar Therapeutics Inc. stock a safe investment in uncertain markets2025 Support & Resistance & Entry Point Strategy Guides - moha.gov.vn

Nov 27, 2025

Monopar Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Free Rapid Portfolio Appreciation - earlytimes.in

Nov 27, 2025

What dividend safety score for Monopar Therapeutics Inc. stockNew Guidance & Free Technical Confirmation Trade Alerts - BỘ NỘI VỤ

Nov 27, 2025

Nov 26, 2025

Is Monopar Therapeutics Inc. stock a safe haven asset2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ

Nov 26, 2025

Nov 23, 2025

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - ADVFN

Nov 23, 2025

Trading Systems Reacting to (MNPR) Volatility - news.stocktradersdaily.com

Nov 23, 2025

Nov 22, 2025